MedTrace Logo

18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer

NCT02809690 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2023-09-07

No results posted yet for this study

Summary

This pilot clinical trial studies how well fluorine F 18 d-FMAU (18F-FMAU) positron emission tomography (PET)/computed tomography (CT) works in diagnosing and characterizing prostate cancer. A PET/CT scan is an imaging test that uses a small amount of radioactive tracer that is given through the vein to take detailed pictures of areas inside the body where the tracer is taken up. Radiotracers such as 18F-FMAU may help to find the cancer and see how far the disease has spread.

Conditions

  • Prostate Neoplasm

Interventions

DEVICE

CAT

Undergo 18F-FMAU PET/CT

DRUG

18F-FMAU

Patients receive radiotracer F 18 d-FMAU IV over 1 minute and then undergo 18F-FMAU PET/CT

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Multiparametric Magnetic Resonance Imaging

Undergo mpMRI

DEVICE

Positron Emission Tomography

Undergo 18F-FMAU PET/CT

DEVICE

Ultrasound

Undergo TRUS-guided biopsy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • National Institute for Biomedical Imaging and Bioengineering (NIBIB)

    collaborator NIH

  • University of Southern California

    lead OTHER

Principal Investigators

  • Hossein Jadvar, MD · University of Southern California

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-12
Primary Completion
2021-07-21
Completion
2021-07-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02809690 on ClinicalTrials.gov